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ABSTRACT
Metastatic breast cancer (BrCa) is still one of the main causes of cancer death 
in women. Metabolic syndrome (MeS), a risk factor for BrCa, is associated to high 
grade tumors, increased metastasis and recurrence of this disease. C-terminal binding 
protein 1 (CTBP1) is a co-repressor of tumor suppressor genes that is activated by 
low NAD+/NADH ratio. Previously, we demonstrated that CTBP1 hyperactivation by 
MeS increased tumor growth in MDA-MB-231-derived xenografts regulating several 
genes and miRNAs. In this work, our aim was to elucidate the role of CTBP1 and 
MeS in BrCa metastasis. We found that CTBP1 protein diminished adhesion while 
increased migration of triple negative BrCa cells. CTBP1 and MeS modulated the 
expression of multiple genes (ITGB4, ITGB6, PRSS2, COL17A1 and FABP4) and 
miRNAs (miR-378a-3p, miR-146a-5p, let-7e-3p, miR-381-5p, miR-194-5p, miR-494-
3p) involved in BrCa progression of MDA-MB-231-derived xenografts. Furthermore, we 
demonstrated that MeS increased lung micrometastasis and liver neoplastic disease 
in mice. CTBP1 hyperactivation seems to be critical for MeS effect on BrCa metastasis 
since CTBP1 depletion completely impaired the detection of circulating tumor cells. 
Our results highlight CTBP1 and MeS impact on BrCa progression positioning them as 
key properties to be considered for BrCa patient prognosis and management.
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INTRODUCTION
Breast cancer (BrCa) is the most common type of 
cancer in women (aside from skin cancer), and it is the main 
cause of death between women [1]. Even though cancer 
is influenced by genetic conditions, there are several risk 
factors such as diet, overweight and sedentary lifestyle that 
could be determinant in the development of this disease [2]. 
According to the National Cholesterol Education 
Program Adult Treatment Panel III (NCEP ATP III) criteria, 
metabolic syndrome (MeS) is a cluster of pathophysiological 
disorders including three or more of the following factors: 
blood-pressure ≥130/85 mm Hg, triglycerides ≥150 mg/
dL, abdominal obesity (waist circumference ≥35 inches in 
women), high density lipoprotein (HDL-C) <50 mg/dL for 
women and fasting glucose ≥ 110 mg/dL [3, 4]. Recently, a 
meta-analysis study had shown that MeS is a risk factor for 
BrCa in general population [5] having a stronger association 
in post-menopausal women [6]. Beside this association, a 
retrospective study demonstrated that MeS has a major 
prevalence in triple negative BrCa (TNBC) rather than in 
other types [7]. Additionally, MeS is associated to high 
grade tumors and higher recurrence rate and metastasis of 
BrCa [8].
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Previously, we reported C-terminal binding protein 
1 (CTBP1), a transcriptional co-repressor of tumor 
suppressor genes [9], as a molecular link between MeS 
and BrCa [10] or prostate cancer [11]. CTBP1 activation 
occurs after dimerization produced by NAD+ or NADH 
binding. CTBP1 has been proposed as a metabolic 
cellular sensor since it shows a higher affinity for NADH 
(>100-fold) compared to NAD+ [12]. Furthermore, we 
found that MeS increased postnatal development of mice 
mammary gland observed as an induction of terminal 
bulbs number. Moreover, we detected epithelial changes 
in mammary ducts with high expression of CTBP1 and 
CCND1 in MeS mice [10]. CTBP1 and MeS increased 
breast tumor growth regulating several genes and 
miRNAs involved in cell proliferation, self-renewal, 
mammary differentiation, cell communication, metabolic 
processes and epithelial-to-mesenchymal transition 
(EMT) in orthotopic xenografts [10]. 
Metastasis is still the main cause of death for BrCa 
patients, and around 30% of women with BrCa diagnosed 
at early stages will progress to metastatic stage. The aim 
of this work was to investigate the role of CTBP1 and 
MeS in BrCa metastasis using a MeS experimental model. 
We found that CTBP1 decreased BrCa cell adhesion and 
migration through expression modulation of multiple 
genes and miRNAs involved in BrCa progression. 
Moreover, CTBP1 and MeS increased circulating tumor 
cells (CTCs) and metastasis in nude mice. 
RESULTS
CTBP1 protein regulates cell adhesion and 
migration of BrCa cells
To analyze CTBP1 role in breast tumor progression, 
we first analyzed CTBP1 modulation effect on MDA-
MB-231, 4T1 and Hs578T BrCa cell adhesion and 
migration, both cell lines representing advanced stages 
of TNBC. In vitro cell adhesion assay with or without 
collagen matrix was performed using stable transfected 
MDA-MB-231 cells with diminished (shRNA CTBP1) or 
control (shRNA Scramble) expression of CTBP1. CTBP1 
protein and mRNA levels in the transfected cell lines 
were assessed by WB (Figure 1A) and RT-qPCR (Figure 
1B–1C), respectively. CTBP1 depletion increased MDA-
MB-231 cell adhesion, both in the presence or absence of 
collagen matrix (Figure 1D, 1E). Additionally, 4T1 and 
Hs578T cells were transiently transfected with CTBP1 
plasmid (pcDNA3 CTBP1) or control (pcDNA3) and cell 
adhesion was determined. As shown in Figure 1F and 1G, 
CTBP1 significantly decreased Hs578T cell adhesion 
without changes in 4T1 cells. 
Cell migration of MDA-MB-231 CTBP1 depleted 
cells (Figure 1A) and 4T1 CTBP1 overexpressing cells 
(Figure 1C) were determined by wound healing assay. 
We found that CTBP1 depletion decreased wound closure 
of these cell lines, and in turn, CTBP1 overexpression 
induced migration (Figure 2A–2D).
In summary, CTBP1 diminished cell adhesion and 
increased cell migration, both initial processes for tumor 
progression, in TNBC cells. 
CTBP1 and MeS modulate multiple genes and 
miRNAs involved in BrCa progression
To study the relevance of CTBP1 and MeS in BrCa 
progression, female nu/nu mice were chronically fed with 
control diet (CD) or high fat diet (HFD) and inoculated 
in the mammary fat pad (MFP) with CTBP1-depleted 
(shRNA CTBP1) or control (shRNA Scramble) MDA-
MB-231 cells. Xenograft samples were collected for 
total RNA isolation and expression of genes involved in 
key processes for BrCa progression was determined by 
RT-qPCR. First, mRNA levels of CTBP family members 
were assessed in order to check that CTBP1 expression 
was diminished without changes in CTBP2 during the 
experiment (Figure 3A). 
Then, we assessed expression of cell adhesion 
genes: COL17A1, FABP4, ITGA1, ITGB4, ITGB6, 
TGM2; cell migration genes: COL17A1, FABP4, ITGB4, 
ITGB6, PRSS2, TGM2 and cell invasion genes: FABP4, 
ITGB4, ITGB6, PRSS2, TGM2. We found that CTBP1 
significantly modulated ITGB4 and PRSS2 genes while 
MeS regulated COL17A1 and FABP4 expression (Figure 
3A). Interestingly, we found that ITGB6 regulation by 
MeS occurred only in xenografts with high CTBP1 
expression (Figure 3A).
Previously, we identified 42 miRNAs involved in 
metabolism, cell cycle and cell communication, regulated 
by CTBP1 in BrCa orthotopic xenografts generated in 
MeS mice [10]. In this work, to elucidate which of these 
miRNAs could be crucial for BrCa development and 
tumor progression, we performed a reactome analysis 
using the bioinformatic resource miRSystem based on the 
number of biological processes regulated by each miRNA. 
We identified a cluster of miRNAs with relevant roles in 
cell proliferation (miR-378a-3p, miR-146a-5p and miR-
381) and tumor progression (miR-378a-3p, miR-146a-5p, 
miR-381, miR-223-3p, miR-494-3p, miR-940, miR-433, 
miR-522 and miR-637) (Supplementary Table 1). Based 
on this analysis we validated these miRNAs by RT-qPCR. 
Also, considering their functions in BrCa progression, we 
included for further studies let-7e-3p [13] and miR-194-
1-5p [14], both identified as CTBP1-regulated miRNAs 
in the microarray. As shown in Figure 3B, using miRNA 
RT-qPCR we found that CTBP1 modulated miR-494-
3p, miR-381-5p, miR-378a-3p, let-7e-3p, miR-194-1-5p 
and miR-146a-5p in MDA-MB-231-derived xenografts 
(Figure 3B). Furthermore, MeS induced miR-381-5p and 
miR-194-1-5p expression (Figure 3B). We were not able 
to validate the expression of miR-940, miR-433-3p and 
miR-637 by RT-qPCR stem loop method.
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Altogether these results suggest that CTBP1 and 
MeS regulate BrCa progression throughout modulation of 
multiple genes and miRNAs.
MeS and CTBP1 increase BrCa lung metastases 
and liver neoplastic disease
We next analyzed the effect of CTBP1 and MeS 
on BrCa metastasis. Thus, MeS female nu/nu mice 
or control were inoculated in the MFP with MDA-
MB-231 shRNA CTBP1 or shRNA Scramble cells. After 
45 days post-injection, lung and liver samples were 
collected for macroscopic, histological and RT-qPCR 
analysis. As previously reported for MDA-MB-231 cell 
line, macroscopic analysis did not reveal the presence 
of metastasis in all experimental groups; however, 
hematoxylin and eosin (H&E) staining and histological 
analysis allowed detection of micrometastases in both 
lung and liver. We found that hyperactivation of CTBP1 
by MeS increased the percentage of mice with lung 
metastases and liver neoplastic disease, which includes 
hepatic micometastasis and intravascular tumor cells 
(Figure 4A and Table 1). Moreover, MeS mice inoculated 
with control cells developed micrometastasis bigger than 
other groups, suggesting that CTBP1 hyperactivation 
by MeS increase both development of metastasis and 
aggressiveness of secondary tumors (Figure 4A). We also 
detected human BrCa cells in lungs by RT-qPCR using 
specific human GAPDH primers. MeS increased the 
amount of human BrCa cells in lungs, and this effect was 
enlarged in mice injected with higher CTBP1 expression 
cells (shRNA Scramble) (Figure 4B). Also, CTCs in mice 
blood were identified by clonogenic assays (Figure 4C 
and Table 2). In agreement to these results, we found that 
CTBP1-depletion completely impaired CTCs from MeS 
mice.
Figure 1: CTBP1 diminishes MDA-MB-231 and Hs578T cell adhesion. CTBP1 expression was determined in MDA-MB-231 
CTBP1 stable depleted (shRNA CTBP1) or control (shRNA Scramble) cells by (A) WB and (B) RT-qPCR. WB quantification of each band 
using Image J software is shown. Data were normalized to LMNA and control cells. CTBP1 mRNA expression levels were normalized 
to ACTB and control (*p value < 0.05). (C) CTBP1 mRNA levels were determined in 4T1 cells transiently transfected with CTBP1 
overexpression (pcDNA3 CTBP1) or control (pcDNA3) vectors by RT-qPCR and normalized to ACTB and control. Cell adhesion assay 
was performed in MDA-MB-231 shRNA CTBP1 or shRNA Scramble cells without (D) or with (E) collagen matrix. The mean and SD 
of one representative experiment (n = 2) with triplicates is shown. Data were normalized to protein and control (*p value < 0.05). (F) Cell 
adhesion assay was performed in 4T1 pcDNA3 CTBP1 or pcDNA3 cells. The mean and SD of one representative experiment (n = 2) with 
triplicates is shown. Data were normalized to control. (G) Cell adhesion assay was performed in Hs578T pcDNA3 CTBP1 or pcDNA3 
cells. The mean and SD of one representative experiment (n = 2) with triplicates is shown. Data were normalized to control. 
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Altogether, these results suggest that CTBP1 
and MeS are key activators of BrCa progression and 
metastasis. 
DISCUSSION
Even though BrCa mortality has been reduced 
over the last decade [15], metastatic BrCa is still one 
of the main causes of cancer death in women, being 
the improvement in the survival rates of patients with 
metastatic BrCa a major concern for public health [16]. 
Once metastasis occurs, BrCa becomes a systemic 
disease and the 5-year survival rate decreases to 20% 
[17]. As well reviewed by Lim et al., the heterogeneity 
between patients will determine the course of the disease 
and it is crucial for treatment decisions [16]. Several 
efforts are being made to elucidate the main sources of 
this heterogeneity. In addition, we propose that patient 
health conditions that impact on cancer progression 
and morbidity, together with their associated molecular 
targets, should be considered for treatment decisions and 
therapies development. Based on this, MeS constitutes 
a health condition related to BrCa recurrence and 
metastasis, that might be identified for differential patient 
management [8]. To understand the molecular mechanism 
underlying BrCa progression connected to MeS might be 
a key aspect for these patients. Previously, we identified 
CTBP1 hyperactivation by MeS as an inductor of breast 
carcinogenesis and tumor growth in mice. In this work, 
we advocated to the study CTBP1 and MeS role over 
BrCa metastasis.
In vitro approaches allowed us to elucidate 
CTBP1 protein effect on adhesion and migration 
of TNBC cells. We first demonstrated that CTBP1 
protein diminished MDA-MB-231 and Hs578T cell 
adhesion. Several studies have shown that CTBP1 
Figure 2: CTBP1 modulates BrCa cell migration. (A) Wound healing assay was performed using MDA-MB-231 CTBP1 stable 
depleted (shRNA CtBP1) or control (shRNA Scramble) cells. Representative pictures of wound at 0, 12 and 16 h from 2 independent 
experiments with triplicates are shown. (B) Percentage of wound closure of MDA-MB-231 shRNA CTBP1 or shRNA Scramble cells 
is shown as mean and SD of one representative experiment (n = 2) with triplicates (*p value < 0.05). (C) Wound healing assay was 
performed using 4T1 pcDNA3 CTBP1 or pcDNA3. Representative pictures of wound at indicated times from 2 independent experiments 
with triplicates are shown. (D) Percentage of wound closure of 4T1 pcDNA3 CTBP1 or pcDNA3 cells is shown as mean and SD of one 
representative experiment (n = 2) with triplicates (*p value < 0.05).
Oncotarget13852www.impactjournals.com/oncotarget
Figure 3: CTBP1 and MeS modulate multiple genes and miRNAs involved in BrCa progression. Expression of the indicated 
mRNAs (A) and miRNAs (B) in xenografts from CD or HFD mice inoculated with MDA-MB-231 shRNA CTBP1 or shRNA Scramble 
cells were determined by RT-qPCR using specific primers. Data were normalized to ACTB and control for mRNAs or to geometric mean 
of miR-103a-3p, miR-191-5p and miR-17-5p and control tumors for miRNAs (*p value < 0.05; **p value < 0.01; ***p value < 0.001).
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modulates the expression of numerous EMT markers, 
such as E-cadherin, in BrCa cells [9, 10]. Di et al. 
and Deng et al. demonstrated that CTBP1 induces a 
mesenchymal phenotype, which is associated with low 
adhesion, high migration and invasion capabilities through 
the regulation of multiple genes [18, 19]. However, this is 
the first study that demonstrates cell adhesion regulation 
by CTBP1 in BrCa cells. We also found that CTBP1 
protein increased the migratory capability of TNBC 
MDA-MB-231 and 4T1 cells. These results support 
previous studies showing that CTBP1 increases migration 
of hormone sensitive MCF-7 BrCa cells [18] and other cell 
types such as glioma cancer cells [20].
Previously, we generated a MeS-like experimental 
model and found that CTBP1 and MeS increased breast 
tumor growth by regulating multiple genes and miRNAs 
Table 1: Quantification of lung metastasis and liver neoplastic disease
Experimental group Lung metastasis  (% of mice)
Liver neoplastic disease  
(% of mice)
shRNA Scramble CD (n = 7) 0 14 iv
shRNA CTBP1 CD (n = 9) 11 0
shRNA Scramble HFD (n = 6) 33 33 iv
shRNA CTBP1 HFD (n = 7) 14 0
Mice were chronically fed with HFD or CD and inoculated with MDA-MB-231 shRNA CTBP1 or shRNA Scramble. Forty-
five days post-injection mice were sacrificed and presence of micrometastasis to lung and liver was determined by histological 
analysis. Percentage of mice with lung metastasis or liver neoplastic disease of each experimental group is informed. In: 
intravenous.
Figure 4: MeS and CTBP1 increase CTCs inducing BrCa lung metastasis and liver neoplastic disease. Mice were fed 
with CD or HFD and inoculated with MDA-MB-231 shRNA CTBP1 or shRNA Scramble cells. Mice were sacrificed 45 days post-injection 
and soft tissue and blood samples were collected. (A) Lung and liver H&E staining is shown. Arrowheads indicate micrometastasis. 
Magnifications ×100. (B) Presence of human BrCa cells in lung of mice was analyzed by determining human GAPDH expression by RT-
qPCR using specific human primers. Data were normalized to mouse ACTB (*p value < 0.05). (C) Clonogenic assay for detection of CTCs 
present in blood of mice was performed in medium supplemented with FBS and puromycin (1 μg/mL). Representative pictures are shown 
(magnifications ×100). Arrowheads indicate colonies.
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involved in cell proliferation, progenitor cells phenotype, 
EMT, mammary development and cell communication 
[10]. To elucidate CTBP1 and MeS effect on BrCa 
progression in vivo, here we analyzed expression levels 
of genes involved in key steps of tumor progression in 
xenografts generated in the MeS-like model. Moreover, 
we showed that CTBP1 induced ITGB4 and PRSS2, while 
MeS regulated COL17A1 and FABP4 genes. In addition, 
MeS induced ITGB6 only in CTBP1-high expression 
xenografts, suggesting that CTBP1 activation by MeS 
could be critical for ITGB6 expression. These results 
support our previous studies showing that, in vivo, CTBP1 
and MeS regulate the mesenchymal markers Vimentin 
and Slug [10]. Importantly, integrins dysregulation is 
associated with cancer development and progression, 
since these are heterodimeric cell surface receptors critical 
for adhesion, migration, invasion, growth, survival and 
differentiation [21]. Interestingly, ITGB4 constitutes a 
marker of basal-like tumors [22] and it is a downstream 
effector of cell migration mediated by the mesenchymal 
marker Vimentin [23], which promotes BrCa invasion 
through the regulation of cytoskeleton dynamics [24]. 
Thus, CTBP1 emerges as a master regulator of EMT 
in BrCa inducing Vimentin and its downstream target 
ITGB4. Also, ITGB6 is a known inductor of cell invasion 
and is a marker of poor prognosis in several cancer types, 
including BrCa [25–28]. Altogether, these results suggest 
that CTBP1 hyperactivation by MeS is a critical event that 
might be considered for prognosis assessment in BrCa 
patients.
CTBP family proteins are encoded by 2 paralogous 
genes, CTBP1 and CTBP2. These proteins display 
redundant functional and structural similarities, although 
each of them also has many distinct roles. However, 
both are oncogenic transcriptional co-regulators 
overexpressed in many cancer types. In this work we 
found that only CTBP1 gene expression was modified 
in the tumors without CTBP2 changes which supports 
the idea that the findings are attributed only to CTBP1.
Previously, we identified 42 miRNAs regulated by 
CTBP1 from xenografts generated in MeS mice [10]. Here, 
we selected a cluster of miRNAs from the microarray data 
based on their function in tumor growth and progression for 
further validation by miRNA RT-qPCR. We demonstrated 
that CTBP1 represses miR-378a-3p and miR-494-3p and 
induces miR-146a-5p and let-7e-3p expression in MDA-
MB-231 xenografts. Furthermore, CTBP1 and MeS regulate 
miR-381-5p and miR-194-1-5p expression. These results 
are consistent with previous studies demonstrating that 
miR-378a-3p expression is reduced in tumor tissue from 
BrCa patients and its expression is associated with better 
prognosis in BrCa patients treated with hormone therapy 
[29]. Also, miR-381-5p expression is reduced in BrCa 
compared to adjacent tissue [30]. Moreover, miR-381-5p 
represses cell proliferation, EMT, invasion and migration of 
MDA-MB-231 [30], suggesting that one of the mechanisms 
involved in CTBP1 role in BrCa adhesion and migration 
is miR-381-5p repression. Interestingly, miR-194-1-5p, 
induced by both CTBP1 and MeS, is increased in serum 
from BrCa patients with recurrence compared to patients 
without recurrence [14]. However, other studies determined 
that miR-146a-5p and let-7e-3p expression, induced by 
CTBP1 in MDA-MB-231 xenografts, correlates with better 
survival in BrCa patients [13, 31]. Furthermore, miR-494-3p 
repressed by CTBP1 hyperactivation by MeS is increased in 
patients with metastatic BrCa compared to patients without 
metastasis [32].
Finally, this is the first report describing CTBP1 
role in BrCa metastasis, and more important how this 
process can be influenced by MeS. We found that MeS 
and CTBP1 increased lung micrometastasis and liver 
neoplastic disease in mice. Importantly, we found that 
CTBP1 expression is crucial for BrCa cells to reach the 
blood stream, since we observed that CTCs, one of the 
major steps for metastatic cascade, were dramatically 
decreased by CTBP1-depletion. 
In summary, in this work we developed an 
experimental model that resembles MeS effect on 
BrCa metastasis. Moreover, we elucidated a molecular 
mechanism that explains MeS association with BrCa 
metastasis based on metastatic cascade activation by 
CTBP1 throughout the regulation of multiple EMT-related 
genes and miRNAs. 
Table 2: Quantification of CTCs from mice
Experimental group % of mice with CTCs
shRNA Scramble CD (n = 6) 33
shRNA CTBP1 CD (n = 6) 50
shRNA Scramble HFD (n = 6) 33
shRNA CTBP1 HFD (n = 6) 0
Mice were chronically fed with HFD or CD and inoculated with MDA-MB-231 shRNA CTBP1 or shRNA Scramble. Forty 
four days post-injection mice were sacrificed and presence of CTCs in blood samples were assessed. Percentage of mice with 
CTCs of each experimental group is shown.
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MATERIALS AND METHODS
Cell culture and transfection
MDA-MB-231 and Hs578T cells and its 
derivatives were grown with DMEM medium (GIBCO) 
supplemented with 10% of fetal bovine serum (FBS) and 
antibiotics. Insulin was added to Hs578T cells. 4T1 cells 
were cultivated with RPMI 1640 medium (Invitrogen) 
supplemented with 10% of FBS and antibiotics. Hs578T 
pcDNA3 CTBP1 and pcDNA3 cells and 4T1 pcDNA3 
CTBP1 and pcDNA3 cells were generated by transient 
transfection as previously described [10]. MDA-MB-231 
shRNA Scramble and MDA-MB-231 shRNA CTBP1 
stable cell lines were previously generated by lentiviral 
transduction [10]. Stable transfected cells were selected 
with 2 µg/mL puromycin (Sigma-Aldrich) for 7 days and 
then maintained with puromycin (1 µg/mL).
Western blot analysis (WB)
MDA-MB-231 cells were lysed and immunoblotted 
as previously described [33] using specific antibodies 
against CTBP1 (BD Transduction Laboratories) and 
LMNA (Santa Cruz Biotechnology Inc.) proteins. Protein 
quantification was performed using Image J 1.48 software.
RNA isolation, cDNA synthesis and qPCR (RT-
qPCR)
Total RNA isolation was performed using Tri 
Reagent (Genbiotech, Buenos Aires, Argentina). cDNA 
was synthesized from 2 μg of RNA using M-MLV 
Reverse Transcriptase (Promega). qPCR was performed 
as previously described [11] using Taq polymerase 
(Embiotec, Buenos Aires, Argentina) in a StepOne 
Plus Real Time PCR (Applied Biosystems). Data were 
normalized to ACTB and control. Primer sequences used 
are shown in Supplementary Table 2. 
miRNA retrotranscription and qPCR (miRNA 
RT-qPCR)
miRNAs were retrotranscribed using stem-
loop method as previously described [34] with some 
modifications. Briefly, 100 ng of total RNA were 
preheated in 14 μL containing 0.07 μM of stem-loop 
primer at 70° C during 5 min. Then, retrotranscription 
was performed using M-MLV Reverse Transcriptase 
(Promega) and incubated in MyGenie96 Thermal Block 
(Bioneer) for 30 min at 16° C, 50 min at 37° C and 15 
min at 70° C. qPCR was performed in 25 μL with 0.05-
1 μL RT product, 1U Taq DNA polymerase (Pegasus), 
4 mM MgCl2, 0.2mM dNTPs, 3 × 10
-5 μL Sybrgreen 
(Sigma), 0.1 μM forward primer and 0.1 μM reverse 
primer. The reactions were incubated in StepOne Plus 
Real Time PCR (Applied Biosystems) at 94° C for 2 
min, followed by 40 cycles of 95° C for 15 s, annealing 
temperature for 20 s and 72° C for 25 s. All reactions were 
run in duplicate. The expression levels of miRNAs were 
normalized to the geometric mean of miR-103a-3p, miR-
191-5p and miR-17a-5p levels as previously described 
[35]. Primer sequences for miRNA RT-qPCR are listed in 
Supplementary Table 2.
Cell adhesion assay
Cell adhesion assay was performed using 96-well 
tissue culture plates with or without collagen coating 
as previously described [36]. Briefly, 12 × 103 MDA-
MB-231/Hs578T derived cells or 24 × 103 4T1 derived cells 
were incubated in 200 μL of medium for 45 or 90 min at 
37° C, respectively. Then, cells were washed with PBS, 
fixed with 100 μL of methanol, stained with 100 μL of 
0.5% crystal violet and washed with PBS. Crystal violet 
was resuspended in 60 μL of 10% methanol and 5% glacial 
acetic acid solution. Absorbance at 620 nm was determined 
using an ELISA Multiskan FC (Thermo Scientific). Data 
were normalized to protein levels from lysates prepared 
using 1.5 × 105 cells from the plates used for each assay. 
Collagen coated plates were made by incubation with 
200 μL of collagen for 1 hour at room temperature.
Wound healing assay
For wound healing assay, 3 × 105 MDA-MB-231 
shRNA Scramble or shRNA CTBP1 cells were seeded in 
12-wells tissue culture plates. After 36 hours, when cells 
reached confluence, a straight wound line was drawn using 
a tip and floating cells were removed with PBS washes. 
For 4T1 cells, 5 × 104 cells were seeded in 12-wells tissue 
culture plates. After 24 hours, cells were transfected 
as previously described [10] using 2 μg of pcDNA3 or 
pcDNA3 CTBP1 vectors. Twenty-four hours later, a 
wound was made as described above. In both cases, cells 
were maintained in 1 mL of medium at 37° C 5% CO2 for 
16 hours in the case of MDA-MB-231 cells, or for 9 hours 
in the case of 4T1 cells. Pictures were obtained using 
Q-Color5 Digital Camera (OLYMPUS) at the indicated 
times after scrape and wound closure quantification was 
performed using ImageJ 1.48.
MeS murine model and orthotopic xenograft
Forty-four female nu/nu mice (4 weeks old) were 
fed ad libitum for 16 weeks with CD (3120 kcal/kg, 
5% fat, n = 22) or HFD (4520 kcal/kg, 37% fat, n = 22) 
generated supplementing chow food with 32% of bovine 
fat first juice (Fatty, Buenos Aires, Argentina) [10]. Body 
weight was determined once a week. After 10 weeks mice 
were divided randomly in two subgroups and inoculated 
with 4.8 × 106 MDA-MB-231 shRNA Scramble or MDA-
MB-231 shRNA CTBP1 cells in the MFP. Tumor size was 
Oncotarget13856www.impactjournals.com/oncotarget
measured 3 times a week and its volume was calculated 
as previously described [10]. Six weeks after inoculation 
mice were sacrificed and tumor, lung, liver and blood 
samples were collected. IHC and histological analysis 
were performed in 5 μm tissue sections using H&E. All 
animal experiments were housed under pathogen free 
conditions following the IBYME’s animal care guidelines.
Tumor and lung tissue samples processing for 
RT-qPCR
Tumor and lung samples were homogenized in Tri 
Reagent (Genbiotech, Buenos Aires, Argentina) using 
Dremel MultiPro 395 and RNA isolation was performed 
as previously described [10]. 
Clonogenic assay and circulating tumor cells 
(CTCs) detection
After 42–45 days post-injection, mice blood 
samples were collected by direct heart puncture and anti-
coagulated using 60 μL 0.5 M EDTA pH = 8. Blood cells 
were harvested by centrifugation and red blood cells were 
lysed by 4 rounds of incubation with ammonium chloride 
potassium (ACK) lysis buffer. Then, blood cells were 
cultivated in 3 wells of a 12-well tissue culture plate with 
750 μL of DMEM supplemented with 10% FBS, 1 µg/mL 
puromycin and antibiotics for eleven days. Pictures were 
obtained using Q-Color5 Digital Camera (OLYMPUS).
Statistical analysis
All results are given as mean and standard deviation 
(SD) of at least three independent experiments unless 
stated otherwise. Student t tests were used to ascertain 
statistical significance with a threshold of p < 0.05. For in 
vivo experiments, two-way ANOVA followed by Tuckey 
test were performed. Shapiro–Wilk and Levene tests were 
used to assess normality and homogeneity of variances. 
*p < 0.05; **p < 0.01;***p < 0.001.
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